These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37757847)

  • 1. Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity.
    Geiger K; Patil A; Budhathoki C; Dooley KE; Lowensen K; Ndjeka N; Ngozo J; Farley JE
    J Acquir Immune Defic Syndr; 2023 Nov; 94(3):253-261. PubMed ID: 37757847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa.
    Geiger K; Patil A; Bergman A; Budhathoki C; Heidari O; Lowensen K; Mthimkhulu N; McNabb KC; Mmed NN; Ngozo J; Reynolds N; Farley JE
    Int J Tuberc Lung Dis; 2024 Jan; 28(1):42-50. PubMed ID: 38178293
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors associated with unfavorable treatment outcomes among multidrug-resistant tuberculosis patients, Sierra Leone: a cross-sectional secondary data analysis.
    Koroma JA; Elduma AH; Sesay U; Gebru GN
    BMC Infect Dis; 2024 Jun; 24(1):579. PubMed ID: 38862873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decentralized, Integrated Treatment of RR/MDR-TB and HIV Using a Bedaquiline-Based, Short-Course Regimen Is Effective and Associated With Improved HIV Disease Control.
    Govender T; Jham MA; Zhang JC; Pillay S; Pak Y; Pillay P; Furin J; Malenfant J; Murphy RA
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):385-392. PubMed ID: 36729541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
    Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
    Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa.
    Lotz JK; Porter J; Conradie H; Boyles T; Gaunt B; Dimanda S; Cort D
    S Afr Med J; 2023 Nov; 113(11):47-56. PubMed ID: 38525642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah T; Ncayiyana J; Padanilam X; Nyasulu PS
    BMC Infect Dis; 2015 Oct; 15():478. PubMed ID: 26511616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine.
    Aibana O; Bachmaha M; Krasiuk V; Rybak N; Flanigan TP; Petrenko V; Murray MB
    BMC Infect Dis; 2017 Feb; 17(1):129. PubMed ID: 28173763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis.
    Bateman M; Wolf A; Chimukangara B; Brust JCM; Lessells R; Amico R; Boodhram R; Singh N; Orrell C; Friedland G; Naidoo K; Padayatchi N; O'Donnell MR
    Clin Infect Dis; 2022 Oct; 75(9):1489-1496. PubMed ID: 35352097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes.
    Geiger K; Patil A; Budhathoki C; Dooley KE; Lowensen K; Ndjeka N; Ngozo J; Farley JE
    PLOS Glob Public Health; 2024; 4(5):e0002714. PubMed ID: 38709764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS.
    O'Donnell MR; Padayatchi N; Wolf A; Zelnick J; Daftary A; Orrell C; Nimmo C; Baldwin M; Boodhram R; Maharaj B; Amico KR; Naidoo K; Friedland G
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):325-332. PubMed ID: 35195572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
    Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of early and interim culture un-conversion in multidrug-resistant/rifampicin-resistant tuberculosis: a retrospective multi-center cohort study in China.
    Chen Q; He W; Du J; Kang W; Zou L; Tang X; Tang P; Guo C; Pan Q; Zhu Q; Yang S; Guo Z; Wu G; Tang S
    Antimicrob Resist Infect Control; 2024 Oct; 13(1):126. PubMed ID: 39407338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.
    Chem ED; Van Hout MC; Hope V
    BMC Infect Dis; 2019 Aug; 19(1):723. PubMed ID: 31420021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
    Bionghi N; Daftary A; Maharaj B; Msibi Z; Amico KR; Friedland G; Orrell C; Padayatchi N; O'Donnell MR
    BMC Infect Dis; 2018 Apr; 18(1):171. PubMed ID: 29642874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S
    Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
    Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
    Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.